Drug Database
UR

Uralyt-K

✓ Approved

Rottapharm Madaus · Small Molecule · Small Molecule

What is Uralyt-K?

Uralyt-K is a small molecule developed by Rottapharm Madaus. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanyRottapharm Madaus
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Rottapharm Madaus

Therapeutic Indications

Uralyt-K is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Renal and urinary disordersCalculus urinary✓ Approved

Related Research Articles

PubMedIranian journal of pharmaceutical research : IJPR2026-09-20

Binding of Epimedium Flavonoids to Human Serum Albumin: Insights from Spectroscopic and Molecular Docking Studies.

Wang Na N, Wang Yuwei Y, Yang Yang Y, Dong Lele L et al.

Epimedin A (EA), epimedin B (EB), and epimedin C (EC), major bioactive flavonoids in Epimedium Herba, have diverse pharmacological activities; however, their interactions with human serum albumin (HSA) remain unclear. This study aimed to investigate the binding mechanisms of EA, EB, and EC to HSA. Multispectroscopic techniques, including UV-vis, fluorescence, and synchronous fluorescence spectroscopy, as well as molecular docking and dynamics simulations, were employed under simulated physiological conditions. Fluorescence spectra were recorded at 298, 303, and 310 K, and molecular docking was performed with HSA (PDB ID: 1BKE). All three flavonoids quenched the intrinsic fluorescence of HSA via static quenching, forming 1:1 complexes with binding constants greater than 104 L·mol-1 (EB > EA > EC at 298 K). Thermodynamic analysis indicated spontaneous binding driven by hydrogen bonds and van der Waals forces. Synchronous fluorescence showed no significant microenvironmental changes around Trp and Tyr residues. Molecular docking and dynamics simulations suggested ligand-dependent differences in the preferred binding regions of HSA. These findings provide preliminary in vitro evidence for the binding of epimedin flavonoids to HSA and may inform future pharmacokinetic investigations.

PMID 42763635
Read full article →
PubMedJournal of materials research2026-09-20

Experimental and computational structure study of the commercial NMC622 lithium-ion battery electrode.

Braun Artur A, Rulev Alexey A, Erat Selma S, Aycibin Murat M et al.

Reliable and traceable characterization of battery electrode materials is essential for standards and harmonized measurements in the growing lithium-ion battery sector. We report a coordinated interfacility study of commercial cathode NMC622, performed within the EURAMET projects OpMetBat and HyMetBat to evaluate reproducibility, uncertainty, and cross-method comparability. A single batch was analyzed using synchrotron X-ray diffraction, high-resolution neutron diffraction at two facilities, transition metal K-edge XANES/EXAFS, DFT-based electronic structure and spectral simulations, and electrochemical measurements. Neutron diffraction yields consistent lattice parameters and transition metal occupancies and enables traceable quantification of lithium content. Lithium loss from neutron refinement agrees with electrochemical charge extraction at low delithiation, whereas deviations at higher states of charge indicate parasitic faradaic processes. XANES and EXAFS confirm local coordination and oxidation states, while DFT reproduces spectral features. Operando impedance correlates with structural evolution and supports state-of-charge metrology. Together, these cross-facility results establish a robust metrological workflow for layered oxide cathode materials. The online version contains supplementary material available at https://doi.org/10.1557/s43578-026-01938-y.

PMID 42763444
Read full article →
PubMedDiabetes, metabolic syndrome and obesity : targets and therapy2026-09-20

Unsupervised Machine Learning of Intrapancreatic Fat Deposition Reveals Distinct Clinical Phenotypes: A CT Study.

Zong Wenlu W, Chu Yuning Y, Guo Yingjie Y, Meng Pin P et al.

Intrapancreatic fat deposition (IPFD) is an ectopic fat phenotype associated with metabolic abnormalities. However, the clinical heterogeneity of IPFD in relation to generalized adiposity remains insufficiently characterized. This study aimed to explore clinical profiles associated with IPFD using unsupervised clustering and characterize their metabolic features. In this retrospective, single-center cross-sectional study, 558 adults undergoing non-contrast abdominal computed tomography were included. K-means clustering was performed using age, body mass index (BMI), pancreas-to-spleen attenuation difference, fasting plasma glucose (FPG), and triglyceride (TG) levels. Clinical characteristics, metabolic comorbidities, and circulating biomarkers were compared across the derived exploratory clusters. Three exploratory clinical phenotypes were identified: an obesity-dominant cluster (n=140), an FPD-like cluster characterized by greater IPFD (n=182), and a reference cluster (n=236). The FPD-like cluster showed the lowest pancreas-to-spleen attenuation difference, older age, and lower BMI than the obesity-dominant cluster. In contrast, the obesity-dominant cluster showed stronger associations with metabolic dysfunction-associated steatotic liver disease and higher uric acid levels. Free fatty acid concentrations were highest in the FPD-like cluster. Differences in glycemic and lipid-related characteristics should be interpreted cautiously because FPG and TG were included as clustering variables. In this exploratory cross-sectional analysis, a cluster characterized by greater IPFD, older age, and lower BMI than the obesity-dominant cluster was associated with less favorable metabolic characteristics. These findings suggest that IPFD may provide complementary information beyond BMI-based assessment; however, the identified clusters should be considered exploratory clinical profiles rather than validated biological subtypes. External validation in independent populations and longitudinal studies are required to confirm their reproducibility and clinical relevance.

PMID 42763730
Read full article →
PubMedMilitary medicine2026-09-20

Multidrug-Resistant Organisms in Combat-Related Injuries: Insights from Iraq, Afghanistan, Ukraine, and Implications for Large-Scale Combat Operations.

Patierno Rena R, Conaway Elwood E, Riberio Marcelo A F MAF

Armed conflict is a powerful driver of antimicrobial resistance, and combat-related infections caused by multidrug-resistant organisms (MDROs) have emerged as a defining challenge of modern military trauma care. Reports from Iraq, Afghanistan, and the ongoing conflict in Ukraine document a clear progression from multidrug-resistant to extensively drug-resistant (XDR) and pan-drug-resistant (PDR) pathogens. This review synthesizes current evidence on combat-related MDRO infections during large-scale combat operations (LSCO) and prolonged field care (PFC). A narrative literature review was conducted using MEDLINE/PubMed for English-language publications from January 2008 through April 2026, combining the terms war, armed conflict, combat injury, Iraq, Afghanistan, Ukraine, antimicrobial resistance, and multidrug-resistant organisms. Eligible sources included peer-reviewed original research, systematic and narrative reviews, and military clinical guidelines. Standard consensus definitions were used for MDR, XDR, and PDR. Combat-related infections are predominantly polymicrobial and dominated by Gram-negative bacilli, particularly Acinetobacter baumannii, Pseudomonas aeruginosa, and carbapenem-resistant Enterobacterales. The Trauma Infectious Disease Outcomes Study (TIDOS) demonstrated MDR Gram-negative infection in approximately 27% of infected casualties from Iraq and Afghanistan. Surveillance from Ukraine reveals a qualitative escalation: meropenem resistance reaches 72% in A. baumannii and 83%-91% in K. pneumoniae, with co-production of NDM-1, OXA-48, and KPC-2 carbapenemases, frequent resistance to last-line agents (cefiderocol, ceftazidime-avibactam), and convergence of resistance and hypervirulence in international high-risk clones. Frontline wound cultures suggest that MDR acquisition is predominantly nosocomial, occurring along the evacuation chain rather than at the point of injury. Repatriation of foreign combatants colonized by XDR organisms now represents an unprecedented international dissemination risk. The MDRO burden in combat casualties is escalating in scale and severity, with direct implications for LSCO and PFC. Mitigation requires standardized antimicrobial protocols across Role 1 and Role 2 levels of care, centralized oversight by the Defense Health Agency, deployable rapid diagnostics, robust stewardship and infection-prevention programs, and resilient logistics-including drone-enabled medical resupply-to maintain antimicrobial effectiveness and operational readiness.

PMID 42763423
Read full article →
PubMedDrug design, development and therapy2026-09-19

Cross-Species Translation and Target-Dependent Pharmacology of GalNAc-siRNAs Using a Multi-Parameter K-PD Framework for Biophase Kinetics, Apparent Potency, and Pharmacodynamic Turnover.

Wu Xiaofei X, Peng Xuanji X, Jia Ranran R, Ma Jiahua J et al.

Small interfering RNAs (siRNAs) conjugated with N-acetylgalactosamine (GalNAc) are liver-targeted therapeutics with sustained activity. However, their cross-species pharmacokinetic (PK) and pharmacodynamic (PD) translation remains poorly defined, particularly regarding target dependence and PD endpoint selection. This study aimed to develop a kinetic-pharmacodynamic (K-PD) modeling framework to characterize their long-term pharmacology, cross-species translational relationships, and target mRNA effects by quantifying biophase half-life, in vivo potency (IDK5 0), and PD turnover. Publicly available PD time-course data for 30 GalNAc-siRNAs across four species (mice, rats, monkeys, and humans) were compiled through a targeted search of the literature and other public sources. A unified K-PD modeling framework was applied to estimate key parameters and evaluate cross-species translational behavior and target-related variability. Human biophase half-life exceeded that in preclinical species, whereas human IDK5 0 was lower. PD half-life in humans approximated that in nonhuman primates. Despite consistent cross-species trends overall, K-PD parameters varied across compounds and targets. PD turnover half-life showed greater within-target consistency than IDK5 0, suggesting differential sensitivity of these endpoints to target biology. The K-PD modeling framework characterized the cross-species pharmacology of GalNAc-siRNAs, confirmed consistent translational patterns, and identified target-specific effects on PD kinetics. These findings facilitate early human pharmacological prediction, enabling a shift from empirical scaling toward model-informed translational decision-making.

PMID 42761645
Read full article →
PubMedJournal of global antimicrobial resistance2026-09-19

Characterization of the novel transposon Tn7722 harboring blaNDM-1: Insights into the evolutionary dynamics of resistance in Klebsiella pneumoniae.

Vo Tram T, Hamieh Aïcha A, Levy Marc M, Pontarotti Pierre P et al.

Klebsiella pneumoniae is an opportunistic pathogen responsible for invasive infections. The rise of carbapenem-resistant K. pneumoniae, largely driven by acquisition of blaNDM genes, represents a global health threat. In French Polynesia, sporadic cases of NDM-producing Enterobacteriales have been reported. This study characterizes the genomic features of NDM-producing K. pneumoniae isolates from French Polynesia and evaluates the roles of clonal expansion and mobile genetic element (MGE)-mediated horizontal gene transfer in blaNDM dissemination. Between July 2006 and September 2021, 17 carbapenemase-producing K. pneumoniae isolates were identified among 715 clinical samples in Tahiti. Whole-genome sequencing using Illumina MiSeq and Oxford Nanopore technologies was performed. Seven NDM-producing K. pneumoniae strains were identified, five blaNDM-1 and two blaNDM-9 variants. All were resistant to ertapenem (MICs 1 to >32 mg/L), with three resistant to imipenem (MICs 8 to >32 mg/L) and six to meropenem (MICs 2 to >8 mg/L). A novel IS26-mediated composite transposon, Tn7722 (16,246 bp), carrying blaNDM-1, qnrS1 and aph(3')-VI genes, was detected in four isolates on IncF and IncR plasmids. Tn7722-like elements were found in diverse bacterial genomes worldwide, suggesting it facilitates blaNDM transmission across multiple species and regions. NDM-producing K. pneumoniae in French Polynesia remain sporadic but genetically diverse, without evidence of local outbreak. This suggests a contribution of plasmid and Tn7722-associated elements to the diversity and evolution of carbapenem resistance. Ongoing genomic surveillance is vital to track the evolution of high-risk clones and MGEs guiding effective containment.

PMID 42763093
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Uralyt-K